| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w13604 |
| 来源ID | Working Paper 13604 |
| Financial Risk in the Biotechnology Industry | |
| Joseph H. Golec; John A. Vernon | |
| 发表日期 | 2007-11-14 |
| 出版年 | 2007 |
| 语种 | 英语 |
| 摘要 | The biotechnology industry has been an engine of innovation for the U.S. healthcare system and, more generally, the U.S. economy. It is by far the most research intensive industry in the U.S. In our analyses in the current paper, for example, we find that, over the past 25 years, average R&D intensity (R&D spending to total firm assets) for this industry was 38 percent. Consider that over this same period average R&D intensity for all industries was only about 3 percent. |
| 主题 | Financial Economics ; Financial Markets ; Corporate Finance ; Health, Education, and Welfare ; Health ; Other ; Law and Economics ; Industrial Organization ; Firm Behavior ; Regulatory Economics ; Industry Studies |
| URL | https://www.nber.org/papers/w13604 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/571280 |
| 推荐引用方式 GB/T 7714 | Joseph H. Golec,John A. Vernon. Financial Risk in the Biotechnology Industry. 2007. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w13604.pdf（252KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
